TY - JOUR
T1 - Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma
AU - Kiyozawa, Daisuke
AU - Kohashi, Kenichi
AU - Takamatsu, Dai
AU - Iwasaki, Takeshi
AU - Shibata, Daiki
AU - Tomonaga, Takumi
AU - Tateishi, Yuki
AU - Eto, Masatoshi
AU - Kinjo, Mitsuru
AU - Nishiyama, Kenichi
AU - Taguchi, Kenichi
AU - Oshiro, Yumi
AU - Kuboyama, Yusuke
AU - Furuya, Mitsuko
AU - Oda, Yoshinao
N1 - Funding Information:
Technical support for the experimental trials was provided by the following laboratory assistants: Motoko Tomita, Jumi Matsumoto, Mami Nakamizo, Kozue Ueno, Naoko Ieiri, Juri Godo, Miki Sashikata, and Haruka Inoue.☆☆ Funding: No funding was received.
Publisher Copyright:
© 2022
PY - 2022/6
Y1 - 2022/6
N2 - Collecting duct carcinoma (CDC) is a rare subset of high-grade renal cell carcinoma (RCC). To diagnose CDC, it is necessary to rule out other renal tumors including renal medullary carcinoma and fumarate hydratase (FH)-deficient RCC. However, there is overlap in the morphology of these three tumors, which all have poor outcomes. There is also still a need to sufficiently examine the therapeutic strategies for each of these tumors. In this study, we retrospectively reclassified invasive/infiltrating high-grade RCC and investigated its pathological features. We reviewed 18 cases previously diagnosed as “CDC,” “FH-deficient RCC,” and “unclassified RCC,” which were reclassified as SMARCB1/INI1-deficient RCC, FH-deficient RCC, and CDC by SMARCB1/INI1, FH, and 2SC immunohistochemistry (IHC) and FH gene mutational status. As the result, 18 cases were reclassified into 2 cases of SMARCB1/INI1-deficient RCC, 7 cases of FH-deficient RCC, and 9 cases of CDC. The morphological features of each group overlapped, and no specific immunohistochemical expression except for SMARCB1/INI1, FH, and 2SC was detected. These results suggest that invasive/infiltrating high-grade RCC should be diagnosed by the combination of immunohistochemistry and molecular biological technique.
AB - Collecting duct carcinoma (CDC) is a rare subset of high-grade renal cell carcinoma (RCC). To diagnose CDC, it is necessary to rule out other renal tumors including renal medullary carcinoma and fumarate hydratase (FH)-deficient RCC. However, there is overlap in the morphology of these three tumors, which all have poor outcomes. There is also still a need to sufficiently examine the therapeutic strategies for each of these tumors. In this study, we retrospectively reclassified invasive/infiltrating high-grade RCC and investigated its pathological features. We reviewed 18 cases previously diagnosed as “CDC,” “FH-deficient RCC,” and “unclassified RCC,” which were reclassified as SMARCB1/INI1-deficient RCC, FH-deficient RCC, and CDC by SMARCB1/INI1, FH, and 2SC immunohistochemistry (IHC) and FH gene mutational status. As the result, 18 cases were reclassified into 2 cases of SMARCB1/INI1-deficient RCC, 7 cases of FH-deficient RCC, and 9 cases of CDC. The morphological features of each group overlapped, and no specific immunohistochemical expression except for SMARCB1/INI1, FH, and 2SC was detected. These results suggest that invasive/infiltrating high-grade RCC should be diagnosed by the combination of immunohistochemistry and molecular biological technique.
UR - http://www.scopus.com/inward/record.url?scp=85128473456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128473456&partnerID=8YFLogxK
U2 - 10.1016/j.humpath.2022.03.002
DO - 10.1016/j.humpath.2022.03.002
M3 - Article
C2 - 35306021
AN - SCOPUS:85128473456
SN - 0046-8177
VL - 124
SP - 36
EP - 44
JO - Human Pathology
JF - Human Pathology
ER -